Adults 18 to 80, any sex, with Nontuberculous Mycobacterium Infection. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent Patients With Negative Sputum CulturePrimary· End of Treatment (Day 15)
Sputum culture will be assessed for any sputum growth. A negative culture represents no mycobacterial growth.
Group
Value
95% CI
Inhaled Nitric Oxide (gNO)
40
Number of Participants With Treatment Related Adverse Events as Assessed by the CTCAE (Common Terminology Criteria for Adverse Events)Secondary· Treatment Day 1 through End of Treatment (3 Months)
Adverse Events will be assessed by patient reporting and routine lab work
Group
Value
95% CI
Inhaled Nitric Oxide (gNO)
6
Number of Participants With a Reduction in Semiquantitative CulturesSecondary· At day 15 from baseline
Semiquantitative Culture Score is an assessment of bacterial burden with a lower score suggesting a lesser bacterial burden. The Semiquantitative Culture Score at Day 15 was compared to baseline, and a reduction in the Semiquantitative Culture Score suggests a reduced bacterial burden with treatment.
Cultures were reported as positive if growth occurs in broth medium only; growth on broth medium plus solid medium cultures with countable colonies will be reported as 0-49 colonies, 1+; solid medium growth with 50-99 colonies, 2+; solid medium growth with 100-199 colonies; 3+, solid medium growt
Group
Value
95% CI
Inhaled Nitric Oxide (gNO)
4
Adverse events — posted to ClinicalTrials.gov
Time frame: Patients were assessed for AE's throughout the duration of the study, approximately 3 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask. Subjects will be treated for 3 weeks (5 days per week) and followed monthly for 3 months.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Nontuberculous Mycobacterium Infection
Currently open trials in the same condition.
NCT06004037 — Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex
· Phase 2
· active not recruiting
NCT04294043 — IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
· Phase 1
· recruiting
NCT04921943 — Hypertonic Saline for MAC
· Phase 4
· recruiting
NCT03120481 — Controls for Respiratory Diseases
· recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
NCT06491264 — Multiparameter Optimized tES for Memory in Aging
· NA
· withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
· Phase 2
· not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE)
· NA
· not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
· Phase 2
· recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 18 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03748992.